Pharmamarketeer

Convert secures €13.6m grant to develop targeted chemo for oxygen-deprived tumours

Belgium’s Convert Pharmaceuticals has secured a €13.6 million grant for initial development efforts on a new targeted chemotherapy drug which could provide benefit in oxygen-deprived cancer cells which older methods have difficulty in treating.

Reageer

Medhc-fases-banner
Advertentie(s)